Bvf Partners L P/il bought $14M of KYMR
director, other at Kymera Therapeutics, Inc.. 317,167 shares at an average of $44.00, traded Jun 30, 2025, filed Jul 1, 2025.
Score components
- +15RoleDirector
- +25Trade size$14.0M at market
- +3Relative to holdingsHoldings up 12%
- +4Price context17% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000921895-25-001910, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 30, 2025 | POpen-market purchase Common Stock, $0.0001 par value | +142,604 | $44.00 | $6.3M | 2,798,795 | Jul 1, 2025 |
| Jun 30, 2025 | POpen-market purchase Common Stock, $0.0001 par value | +115,783 | $44.00 | $5.1M | 2,219,858 | Jul 1, 2025 |
| Jun 30, 2025 | POpen-market purchase Common Stock, $0.0001 par value | +58,780 | $44.00 | $2.6M | 353,412 | Jul 1, 2025 |
| Jun 25, 2025 | AGrant or award Stock Option (Right to Buy)derivativeindirect: See footnote | +16,000 | $0.00 | $0 | 16,000 | Jul 1, 2025 |
Related signals
Other insiders at Kymera Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $3.4M 30,000 shares | -4% | |
| 41Moderate | KYMRsell Kymera Therapeutics, Inc. | Brian Adams Chief Legal Officer | $744k 6,371 shares | -11% | |
| 38Weak | Kymera Therapeutics, Inc. | Jeremy G Chadwick Chief Operating Officer | $9.0M 115,977 shares | -76% | |
| 20Weak | Kymera Therapeutics, Inc. | Pamela Esposito director | $198k 2,500 shares | -100% | |
| 35Weak | Kymera Therapeutics, Inc. | Jeremy G Chadwick Chief Operating Officer | $2.1M 25,758 shares | -27% | |
| 35Weak | Kymera Therapeutics, Inc. | Bruce Booth director | $7.4M 81,866 shares | -2% | |
| 53Moderate | Kymera Therapeutics, Inc. | Jeremy G Chadwick Chief Operating Officer | $516k 5,958 shares | -7% | |
| 54Moderate | Kymera Therapeutics, Inc. | Jared Gollob Chief Medical Officer | $917k 10,508 shares | -8% | |
| 62Notable | Kymera Therapeutics, Inc. | Bruce N. Jacobs Chief Financial Officer | $1.1M 12,471 shares | -5% | |
| 30Weak | Kymera Therapeutics, Inc. | Nello Mainolfi Chief Executive Officer | $2.7M 30,000 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.